Enbrel, Humira "still mainstay" first-line US RA biologics PharmaTimes In addition, treating physicians told the study that they would consider switching 22%-34% of their patients who are currently being treated with Orencia IV, and 20%-25% of their patients who are receiving Genentech/Biogen Idec's Rituxan (rituximab) or ... |
